Focus: Biomea Fusion is a public biotech company focused on small-molecule cancer therapeutics, headquartered in San Carlos, CA and founded in 2017. The company operates as a clinical-stage biotech with a diversified pipeline spanning oncology and metabolic diseases.
Profile data last refreshed 11h ago · AI intelligence enriched 2w ago
Stable — net +1 jobs in 30d
1 added, 0 removed. Backfill posture.
Biomea Fusion is a speculative clinical-stage play best suited for scientists and translational roles willing to bet on pipeline progression; career stability is dependent on Phase 2 data success and capital markets appetite.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Biomea Fusion
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Biomea Fusion's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Biomea reports early weight-loss signal for oral GLP-1 drug, seeks development partner - AllSci
Biomea reports early weight-loss signal for oral GLP-1 drug, seeks development partner AllSci
Biomea posts phase 1 data to pitch oral GLP-1 to potential partners, but investors appear unconvinced - Fierce Biotech
Biomea posts phase 1 data to pitch oral GLP-1 to potential partners, but investors appear unconvinced Fierce Biotech
Biomea Fusion to release Phase I data for oral GLP-1 drug BMF-650 - StreetInsider
Biomea Fusion to release Phase I data for oral GLP-1 drug BMF-650 StreetInsider
Biomea Fusion (Nasdaq:BMEA) - Stock Analysis - Simply Wall Street
Biomea Fusion (Nasdaq:BMEA) - Stock Analysis Simply Wall Street
Biomea Fusion Completes Key Phase 2 Trial in Type 1 Diabetes: What Investors Should Watch Next - TipRanks
Biomea Fusion Completes Key Phase 2 Trial in Type 1 Diabetes: What Investors Should Watch Next TipRanks
Here's Why We're Watching Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation - Simply Wall Street
Here's Why We're Watching Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation Simply Wall Street
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 7 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo